Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases

Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation Acquisition builds on Lilly's established capabilities in inflammatory-mediated diseases INDIANAPOLIS , Jan. 7, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and